SCHEMBL164686

SCHEMBL164686

O=C1N=CC2=NC=CC2=N1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4697735 0.73
SCHEMBL7215917 0.67
SCHEMBL866248 0.65
Hydrochloric Acid SCHEMBL18422639 0.65
SCHEMBL2398119 0.64
SCHEMBL7545259 0.64 MAPT (0.43)
SCHEMBL27388424 0.64
SCHEMBL3035541 0.62
SCHEMBL16830833 0.62
SCHEMBL29526981 0.61

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 459 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250313588-A1 NOVEL PYRROLOPYRIMIDINONE CARBOXAMIDE COMPOUND FOR INHIBITING CDK, STEREOISOMER THEREOF OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING SAME AS ACTIVE INGREDIENT UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION (KR) 2025-10-09 US claimed
CN-115073470-B Pyrrolopyrimidinone derivative, and preparation method and application thereof 南京中瑞药业有限公司 2025-02-11 CN claimed
US-20240208912-A1 MTA-Cooperative PRMT5 Inhibitors MIRATI THERAPEUTICS INC (US) 2024-06-27 US claimed
EP-4304720-A1 MTA-COOPERATIVE PRMT5 INHIBITORS Mirati Therapeutics, Inc. (US) 2024-01-17 EP claimed
WO-2023219427-A1 NOVEL PYRROLOPYRIMIDINONE CARBOXAMIDE COMPOUND FOR INHIBITING CDK, STEREOISOMER THEREOF OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING SAME AS ACTIVE INGREDIENT 서울대학교산학협력단 2023-11-16 WO claimed
CN-114761410-B Pyrrolopyrimidinone compounds and application thereof 广州必贝特医药股份有限公司 2023-08-25 CN claimed
CN-115414480-A Dianhydrogalactitol in combination with radiation for treatment of non-small cell lung cancer and glioblastoma multiforme 德玛医药 2022-12-02 CN claimed
WO-2022213932-A1 PYRROLOPYRIMIDINONE COMPOUND AND APPLICATION THEREOF 广州必贝特医药股份有限公司 2022-10-13 WO claimed
CN-115073470-A Pyrrolopyrimidinone derivative and preparation method and application thereof 南京中瑞药业有限公司 2022-09-20 CN claimed
WO-2022192745-A1 MTA-COOPERATIVE PRMT5 INHIBITORS Mirati Therapeutics, Inc. (US) 2022-09-15 WO claimed
US-20100069632-A1 SALTS OF PYRROLOPYRIMIDINONE DERIVATIVES AND PROCESS FOR PREPARING THE SAME SK CHEMICALS CO., LTD (KR) 2010-03-18 US claimed
JP-2009542633-A 2009-12-03 JP claimed
EP-2038282-A1 SALTS OF PYRROLOPYRIMIDINONE DERIVATIVES AND PROCESS FOR PREPARING THE SAME SK Chemicals, Co., Ltd. (KR) 2009-03-25 EP claimed
WO-2008004796-A1 SALTS OF PYRROLOPYRIMIDINONE DERIVATIVES AND PROCESS FOR PREPARING THE SAME SK CHEMICALS CO., LTD. (KR) 2008-01-10 WO claimed
EP-1551962-A4 MITOTIC KINESIN BINDING SITE MERCK & CO INC (US) 2007-08-01 EP claimed
EP-1551962-A2 MITOTIC KINESIN BINDING SITE Merck & Co., Inc. (US) 2005-07-13 EP claimed
WO-2004004652-A2 MITOTIC KINESIN BINDING SITE MERCK & CO., INC. (US) 2004-01-15 WO claimed
US-6346359-B1 FORMS COLOR BY REACTION WITH DIAZONIUM SALT; COLORFASTNESS, STORAGE STABILITY, SHELF LIFE; PURPLE AND CYAN HUES FUJI PHOTO FILM CO., LTD. (JP) 2002-02-12 US claimed
EP-0682027-B1 Pyrrolopyrimidine derivatives with antiproliferative action CIBA GEIGY AG (CH) 1997-10-15 EP claimed
EP-0682027-A1 Pyrrolopyrimidine derivatives with antiproliferative action CIBA-GEIGY AG (CH) 1995-11-15 EP claimed